Skip to contentE
Endovia Health Sciences, Inc.
E
EDVAEndovia Health Sciences, Inc. Q3 2019 · 10-Q
Revenue$305.20K$305.20K−2.5% vs Q3 2018 Net Income-$53.98K-$53.98KN/M vs Q3 2018 EPS Diluted-$0.03-$0.03— vs Q3 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endovia Health Sciences, Inc. · CIK 1553788 · Engraved from SEC EDGAR
Operating Cash Flowderived-$510,240N/M Free Cash Flowderived-$515,656N/M Margins · derivedGross margin-4.6%−57.3 pt vs Q3 2018
Operating margin-282.3%−281.6 pt vs Q3 2018
Net margin-17.7%−16.1 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 14, 2019 · 45 d after period end